1 research outputs found
PEGylated Triacontanol Substantially Enhanced the Pharmacokinetics of Triacontanol in Rats
Triacontanol (TA), a natural compound
with various health benefits,
is extensively used as a nutritional supplement. The therapeutic and
nutraceutical applications of TA are limited due to its poor aqueous
solubility. PEGylated triacontanol (PEGylated TA) was designed to
improve the solubility and pharmacokinetics of TA. After PEGylation,
the solubility (∼250 g·L<sup>–1</sup> versus 9
× 10<sup>–14</sup> g·L<sup>–1</sup>), body
residence (MRT, 9.40 ± 2.03 h versus 2.59 ± 0.705 h, <i>p</i> < 0.001), and systemic exposure (AUC<sub>0–inf,</sub> 29.1 ± 5.33 μM·h versus 0.529 ± 0.248 μM·h, <i>p</i> < 0.001) of TA were all significantly increased compared
to pristine TA. When intravenously administered (6.85, 22.8, and 68.5
μmol·kg<sup>–1</sup>) in rats, PEGylated TA exhibited
a slow clearance (44.8 ± 8.62, 47.9 ± 5.18, and 46.9 ±
16.5 mL·h<sup>–1</sup>·kg<sup>–1</sup>), long
elimination half-life (8.76 ± 0.96, 10.4 ± 1.66, and 11.1
± 2.81 h), and abundant systemic exposure (AUC<sub>0–<i>t</i></sub>, 155 ± 24.2, 523 ± 56.2, and 1709 ±
245 μM·h). Meanwhile, its metabolite TA showed a high AUC<sub>0–<i>t</i></sub> (28.4 ± 5.14, 151 ± 25.4,
and 797 ± 184 μM·h) and slow elimination (<i>t</i><sub>1/2</sub>, 10.1 ± 2.03, 7.78 ± 1.74, and
6.82 ± 0.58 h). Our results demonstrated that PEGylated TA has
superior pharmacokinetics, which enhanced its nutritional and pharmacodynamic
potency, and thus warrants further investigations